2019 CYIR Finalized

24 associated with the use of bedaquiline, linezolid, levo- floxacin, moxifloxacin, clofazimine, and carbapenems; the first 4 drugs listed were associated with reduced mortality. Amikacin was associated with greater success in treating susceptible isolates, whereas kanamycin and capreomycin were associated with worse outcomes regardless of sus- ceptibility. Pyrazinamide, cycloserine, and terizidone were associated with modest benefit when treating susceptible isolates. Ethambutol, ethionamide, and PAS were not asso- ciated with improved outcomes regardless of susceptibility results. The use of at least 5 drugs in the initial phase and at least 4 drugs in the continuation phase was associated with decreased mortality. Outcomes were improved when the initial phase was continued for 5-7 months and total treatment length continued for 15-18 months, after sputum culture conversion. Comments 1. This study highlights the importance of bedaquiline, linezolid and later generation fluoroquinolones for treating MDR-TB, demonstrates a lack of equivalency among the injectables, and shows a lack of benefit of several commonly used drugs for the treatment of MDR-TB. 2. Although studies included in the meta-analysis are susceptible to confounding (i.e., observational studies, individualized treat- ments), the investigators attempted to address this concern through propensity score matching and sensitivity analyses that demonstrated robust findings. 3. These results have informed WHO MDR-TB guidelines to pref- erentially use Group A (levofloxacin/moxifloxacin, bedaquiline, linezolid) and Group B (clofazimine, cycloserine/terizidone) medications, and de-emphasize injectables based on poor effectiveness and/or drug-related toxicities. 4. These results underscore the importance of expanding global laboratory capacity to test first- and second-line drug suscep- tibility. 5. Ensuring access to Groups A and B medications is vital to addressing the drug-resistant TB epidemic. TB DIAGNOSIS Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, Hall SL, Chakravorty S, Cirillo DM, Tukvadze N, Bablishvili N, Stevens W, Scott L, Rodrigues C, Kazi MI, Joloba M, Nakiyingi L, Nicol MP, Ghebrekristos Y, Anyango I, Murithi W, Dietze R, Lyrio Peres R, Skrahina A, Auchynka V, Chopra KK, Hanif M, Liu X, Yuan X, Boehme CC, Ellner JJ, Denkinger CM. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis 2018; 18: 76-84. Summary In 2010, WHO endorsed GeneXpert MTB/RIF (Xpert), a rapid, automated, nucleic acid amplification test, that can detect TB and rifampin resistance. Due to Xpert’s decreased sensitivity in detecting paucibacillary TB, Xpert MTB/RIF Ultra (Ultra), a new cartridge that runs on the same Xpert device after a software upgrade, was developed with improved sensitivity. Investigators performed a prospective study in 8 medium/high-TB burden countries to compare Ultra accuracy to Xpert for detection of TB and rifampin resistance. Individuals with pulmonary TB symptoms were recruited into a TB case detection group or MDR-TB high- risk group. Three sputum samples were collected over 2 days for testing with Xpert and Ultra (sample 1), and solid and liquid culture (samples 2 and 3, both media). 1753 par- ticipants were included in analyses (1439 case detection, 314 MDR-TB high risk group). 39% of participants were culture-positive for M. tuberculosis, of whom 31% had rifampin-resistant TB. Ultra was more sensitive for detect- ing TB overall (88%) and among smear-negative/culture- positive samples (63%), compared with Xpert (83% and 46%, respectively). Ultra was less specific for TB detection (96%) than Xpert (98%), particularly in participants with a prior history of TB (Ultra=93%, Xpert=98%). Both tests had similar accuracy for detecting rifampin resistance. Comments 1. Ultra is a more sensitive test for TB than Xpert with significant improvements in detecting AFB-smear negative disease. 2. Ultra is less specific than Xpert and as Ultra is rolled-out glob- ally, these differences in accuracy may have important ramifica- tions depending on TB prevalence 3. A new result category has been added to Ultra, “trace call”, that corresponds to the lowest bacillary burden for M. tuberculosis detection, and WHO has issued recommendations on interpret- ing trace calls. 4. The impact of Ultra on patient outcomes needs to be studied, especially since Xpert has not been definitively shown to affect time to TB diagnosis, initiation of anti-TB treatment, or reduce mortality. TREATMENT OF PULMONARY MYCOBACTERIUM AVIUM COMPLEX Griffith DE, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O’Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace Jr. RJ, van Ingen J, Coulter C, Nezamis J, Winthrop KL. Amikacin liposome inhalation sus- pension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). Am J Respir Crit Care Med 2018; 198:1559-1569. Summary Nontuberculous mycobacterial (NTM) lung disease is more common than TB in the U.S. and is increasing in preva- lence. Amikacin liposome inhalation suspension (ALIS), penetrates mycobacterial biofilms, and increases amikacin uptake by alveolar macrophages compared to non-lipo- somal amikacin preparations. A phase 3 industry-funded international study investigated ALIS efficacy when added to guideline-based therapy (GBT) compared to GBT alone. This was an interim analysis of an ongoing open-label, non-placebo-controlled study. Eligible participants were MYCOBACTERIAL INFECTIONS

RkJQdWJsaXNoZXIy MTM1ODMw